Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$0.93 USD
-0.03 (-2.93%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $0.94 +0.01 (0.86%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OVID 0.93 -0.03(-2.93%)
Will OVID be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OVID based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OVID
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
OVID: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates
Other News for OVID
Ovid Therapeutics Announces Leadership Transition and Consulting Deal
Ovid Therapeutics to Present at Upcoming August Investor Conferences
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ovid Therapeutics (OVID) and Dexcom (DXCM)
Buy Rating Affirmed for Ovid Therapeutics on Advisory Expansion and Promising Epilepsy Drug Prospects
The Latest Analyst Ratings For Ovid Therapeutics